CA3199806A1 - Methods of reducing tau in human subjects - Google Patents

Methods of reducing tau in human subjects

Info

Publication number
CA3199806A1
CA3199806A1 CA3199806A CA3199806A CA3199806A1 CA 3199806 A1 CA3199806 A1 CA 3199806A1 CA 3199806 A CA3199806 A CA 3199806A CA 3199806 A CA3199806 A CA 3199806A CA 3199806 A1 CA3199806 A1 CA 3199806A1
Authority
CA
Canada
Prior art keywords
seq
amino acid
acid sequence
chain variable
tau
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3199806A
Other languages
English (en)
French (fr)
Inventor
Wendy R. GALPERN
Maarten TIMMERS
Tom Lieven K. JACOBS
Partha NANDY
Lingjue Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of CA3199806A1 publication Critical patent/CA3199806A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
CA3199806A 2020-10-26 2021-10-25 Methods of reducing tau in human subjects Pending CA3199806A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063105804P 2020-10-26 2020-10-26
US63/105,804 2020-10-26
PCT/EP2021/079543 WO2022090158A1 (en) 2020-10-26 2021-10-25 Methods of reducing tau in human subjects

Publications (1)

Publication Number Publication Date
CA3199806A1 true CA3199806A1 (en) 2022-05-05

Family

ID=78402146

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3199806A Pending CA3199806A1 (en) 2020-10-26 2021-10-25 Methods of reducing tau in human subjects

Country Status (11)

Country Link
US (1) US20220127345A1 (https=)
EP (1) EP4232155A1 (https=)
JP (1) JP2023546504A (https=)
KR (1) KR20230093499A (https=)
CN (1) CN116916955A (https=)
AU (1) AU2021367878A1 (https=)
CA (1) CA3199806A1 (https=)
IL (1) IL302386A (https=)
MX (1) MX2023004831A (https=)
TW (1) TW202233666A (https=)
WO (1) WO2022090158A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3093200A1 (en) 2018-03-05 2019-09-12 Janssen Pharmaceutica Nv Anti-phf-tau antibodies and uses thereof
JP7379764B1 (ja) 2022-08-09 2023-11-15 レール・リキード－ソシエテ・アノニム・プール・レテュード・エ・レクスプロワタシオン・デ・プロセデ・ジョルジュ・クロード 空気分離装置および空気分離方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
JP6214161B2 (ja) * 2009-12-21 2017-10-18 ジェネンテック， インコーポレイテッド 抗体製剤
ITMI20120814A1 (it) * 2012-05-11 2013-11-12 Diego Dolcetta Somministrazione intratecale, preferibilmente intraventricolare, di inibitori di mtor per la terapia di alcune malattie neurodegenerative, neuro-infiammatorie, neuro-oncologiche
US8980270B2 (en) * 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
CN117820467A (zh) * 2016-12-07 2024-04-05 基因泰克公司 抗tau抗体和使用方法
TWI771389B (zh) * 2017-03-16 2022-07-21 美商健生生物科技公司 抗phf-tau抗體及其用途
MA53338A (fr) * 2018-03-05 2022-01-05 Janssen Pharmaceutica Nv Dosages pour détecter la neurodégénérescence
WO2020223279A1 (en) * 2019-04-29 2020-11-05 Voyager Therapeutics, Inc. VECTORIZED ANTIBODIES (vAb) AND USES THEREOF
EP4232472A1 (en) * 2020-10-26 2023-08-30 JANSSEN Pharmaceutica NV Method of safe administration of anti-tau antibody

Also Published As

Publication number Publication date
MX2023004831A (es) 2023-07-12
TW202233666A (zh) 2022-09-01
US20220127345A1 (en) 2022-04-28
KR20230093499A (ko) 2023-06-27
IL302386A (en) 2023-06-01
AU2021367878A1 (en) 2023-06-22
JP2023546504A (ja) 2023-11-02
EP4232155A1 (en) 2023-08-30
WO2022090158A1 (en) 2022-05-05
CN116916955A (zh) 2023-10-20

Similar Documents

Publication Publication Date Title
RU2518351C2 (ru) Антитела к рецептору конечных продуктов глубокого гликирования (rage) и их применения
US8026342B2 (en) Compositions and methods for binding sphingosine-1-phosphate
TWI634126B (zh) 抗－N3pGlu 類澱粉β肽抗體及其用途
JP2024534488A (ja) ジストロフィノパチーを処置するための筋標的化複合体の投与
TW201713687A (zh) 抗－ｔａｕ抗體及使用方法
US20230123110A1 (en) High dose treatments for alzheimer's disease
TWI537003B (zh) ＩＬ-１β化合物之新穎用途
CN106163548A (zh) 治疗阿尔茨海默氏病的方法
US20240025978A1 (en) Methods for treating complement-mediated diseases
JP2025508757A (ja) 抗ｔｒｅｍ２抗体の使用方法
US20220127345A1 (en) Methods of Reducing Tau in Human Subjects
US20220127346A1 (en) Methods of Safe Administration of Anti-Tau Antibody
KR20250107906A (ko) 항-N3pGlu 아밀로이드 베타 항체, 그의 용량 및 용도
JP2024547001A (ja) 抗アミロイドβプロトフィブリル抗体及び抗タウ抗体を使用する方法
JP2022549218A (ja) 抗トリプターゼ抗体の投薬
Class et al. Patent application title: Methods of Reducing Tau in Human Subjects
EA052839B1 (ru) Способы снижения уровня тау-белка у человеческих индивидов
EA050381B1 (ru) Способы снижения уровня тау-белка у человеческих индивидов
HK40100364A (zh) 减少人类受试者中的tau的方法
JP2024517796A (ja) 抗ｂａｆｆｒ抗体を使用するループス腎炎の治療
EA051320B1 (ru) Способ безопасного введения антитела к тау-белку
CN116829582A (zh) 安全施用抗Tau抗体的方法
WO2024112561A1 (en) Methods for the treatment of myasthenia gravis
HK40067504A (en) High dose treatments for alzheimer's disease
HK40068762A (en) High dose treatments for alzheimer's disease

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250902

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250902

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20251023

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20251023

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251023

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20251223

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20251223

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20251223

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20251223

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251223

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260106